Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Hany Massarany Biography and Net Worth

Director of Accelerate Diagnostics

Hany Massarany has served as a Director of the Company since May 2021. Mr. Massarany was President and Chief Executive Officer of GenMark Diagnostics, Inc., a leading provider of automated multiplex molecular diagnostic testing systems, from April 2011 to March 2020. From February 2009 to April 2011, Mr. Massarany served as President of Ventana Medical Systems and Head of Roche Tissue Diagnostics, a division of F. Hoffman-La Roche Ltd. which develops and manufactures instruments and test reagents that automate tissue-based cancer diagnostics. From 1999 to 2009, Mr. Massarany held various global leadership positions with Ventana Medical Systems and prior to that, he also held executive management positions with Bayer Diagnostics and Chiron Diagnostics, working in both the Asia Pacific region and the United States. Mr. Massarany served on the board of directors of GenMark Diagnostics, Inc. from May 2011 to February 2020, and currently serves on the board of Biodesix, Inc. Mr. Massarany earned a B.S. in Microbiology and Immunology from Monash University in Australia and an M.B.A. from Melbourne University.

What is Hany Massarany's net worth?: The estimated net worth of Hany Massarany is at least $127,244.12 as of November 21st, 2022. Mr. Massarany owns 137,934 shares of Accelerate Diagnostics stock worth more than $127,244 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Massarany may own. Learn More about Hany Massarany's net worth.
How do I contact Hany Massarany?: The corporate mailing address for Mr. Massarany and other Accelerate Diagnostics executives is 3950 South Country Club Suite 470, Tucson AZ, 85714. Accelerate Diagnostics can also be reached via phone at (520) 365-3100 and via email at [email protected]. Learn More on Hany Massarany's contact information.
Has Hany Massarany been buying or selling shares of Accelerate Diagnostics?: Hany Massarany has not been actively trading shares of Accelerate Diagnostics over the course of the past ninety days. Most recently, on Monday, January 31st, Hany Massarany bought 2,000 shares of Accelerate Diagnostics stock. The stock was acquired at an average cost of $33.00 per share, with a total value of $66,000.00. Learn More on Hany Massarany's trading history.
Who are Accelerate Diagnostics' active insiders?: Accelerate Diagnostics' insider roster includes Hany Massarany (Director), Jack Phillips (CEO), Ron Price (Insider), Steven Reichling (CFO), and Jack Schuler (Director). Learn More on Accelerate Diagnostics' active insiders.
Are insiders buying or selling shares of Accelerate Diagnostics?: During the last twelve months, insiders at the medical research company sold shares 24 times. They sold a total of 107,388 shares worth more than $145,458.61. The most recent insider tranaction occured on April, 17th when CEO Jack Phillips sold 26,735 shares worth more than $20,853.30. Insiders at Accelerate Diagnostics own 43.6% of the company. Learn More about insider trades at Accelerate Diagnostics.
Information on this page was last updated on 4/17/2024.

Hany Massarany Insider Trading History at Accelerate Diagnostics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/31/2022	Buy	2,000	$33.00	$66,000.00
9/27/2021	Buy	1,000	$53.00	$53,000.00

Hany Massarany Buying and Selling Activity at Accelerate Diagnostics

Accelerate Diagnostics Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.

Today's Range

Now: $0.94

$0.89

$0.95

50 Day Range

MA: $0.97

$0.74

$1.19

2 Week Range

Now: $0.94

$0.73

$11.90

Volume

14,119 shs

Average Volume

114,635 shs

Market Capitalization

$20.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52